Cuba Launches World’s First Vaccine against Lung Cancer

HEALTH, 9 Jan 2012

ZeitNews – TRANSCEND Media Service

From the island nation known for the quality of its cigars comes some pretty big news today [3 Jan 2012]: Xinhua reports that Cuban medical authorities have released the first therapeutic vaccine for lung cancer. CimaVax-EGF is the result of a 25-year research project at Havana’s Center for Molecular Immunology, and it could make a life or death difference for those facing late-stage lung cancers, researchers there say.

CimaVax-EGF isn’t a vaccine in the preventative sense–that is, it doesn’t prevent lung cancer from taking hold in new patients. It’s based on a protein related to uncontrolled cell proliferation–that is, it doesn’t prevent cancer from existing in the first place but attacks the mechanism by which it does harm.

As such it can turn aggressive later-stage lung cancer into a manageable chronic disease by creating antibodies that do battle with the proteins that cause uncontrolled cell proliferation, researchers say. Chemotherapy and radiotherapy are still recommended as a primary means of destroying cancerous tissue, but for those showing no improvement the new vaccine could be a literal lifesaver.

The vaccine has already been tested in 1,000 patients in Cuba and is being distributed at hospitals there free of charge. That’s a big deal for a country where smoking is part of the national culture and a leading cause of death. If it proves as successful as researchers say it is, it should give those suffering from lung cancer reason to celebrate–just not with a Cohiba.

Source: PopSci

Go to Original – zeitnews.org

Share this article: email mastodon facebook 🔗 copy link

DISCLAIMER: The statements, views and opinions expressed in pieces republished here are solely those of the authors and do not necessarily represent those of TMS. In accordance with title 17 U.S.C. section 107, this material is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes. TMS has no affiliation whatsoever with the originator of this article nor is TMS endorsed or sponsored by the originator. “GO TO ORIGINAL” links are provided as a convenience to our readers and allow for verification of authenticity. However, as originating pages are often updated by their originating host sites, the versions posted may not match the versions our readers view when clicking the “GO TO ORIGINAL” links. This site contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available in our efforts to advance understanding of environmental, political, human rights, economic, democracy, scientific, and social justice issues, etc. We believe this constitutes a ‘fair use’ of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, the material on this site is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes. For more information go to: http://www.law.cornell.edu/uscode/17/107.shtml. If you wish to use copyrighted material from this site for purposes of your own that go beyond ‘fair use’, you must obtain permission from the copyright owner.

Comments are closed.